Table 3.
Univariate Cox proportional hazard regression analysis for overall survival and relapse-free survival in stage I and II osteosarcoma patients
| Characteristics | No. | OS | P | RFS | P |
|---|---|---|---|---|---|
| HR (95% CI) | HR (95% CI) | ||||
| Age, yr., ≥ 30 (vs. < 30) | 8/30 | 1.785 (0.535–5.959) | 0.346 | 2.491 (0.860–7.211) | 0.092 |
| Sex, male (vs. female) | 20/30 | 1.428 (0.383–5.331) | 0.596 | 1.939 (0.532–7.065) | 0.316 |
| Tumor size, cm, > 8 (vs. ≤ 8) | 12/30 | 1.194 (1.037–1.374) | 0.014 | 2.628 (0.901–7.662) | 0.077 |
| Stage, II (vs. I) | 19/30 | 8.998 (1.158–69.931) | 0.036 | 10.325 (1.347–79.152) | 0.025 |
| Histological grade, high (vs. low) | 19/30 | 8.998 (1.158–69.931) | 0.036 | 10.325 (1.347–79.152) | 0.025 |
| PARP1, positive (vs. negative) | 21/30 | 6.780 (0.872–52.737) | 0.067 | 7.310 (0.954–56.000) | 0.055 |
| γH2AX, positive (vs. negative) | 17/30 | 15.788 (2.013–123.838) | 0.009 | 8.414 (1.847–38.322) | 0.006 |
| BRCA1, positive (vs. negative) | 14/30 | 4.428 (1.193–16.439) | 0.026 | 6.323 (1.745–22.916) | 0.005 |
| BRCA2, positive (vs. negative) | 11/30 | 4.372 (1.297–14.734) | 0.017 | 2.898 (0.982–8.554) | 0.054 |
| CSddrm, score 3–4 (vs. score 0–2) | 14/30 | 30.043 (3.724–242.374) | 0.001 | 27.986 (3.501–223.717) | 0.002 |
OS overall survival, RFS relapse-free survival, HR hazard ratio, 95% CI 95% confidence interval, CSddrm the combined score for the immunohistochemical expression of PARP1, γH2AX, BRCA1, and BRCA2